May 3, 2010 - ANTHERA PHARMACEUTICALS ANNOUNCES ADDITIONAL DATA FROM FRANCIS STUDY – Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced detailed results from a new biomarker analysis of the FRANCIS study. FRANCIS examined the effects of once-daily varespladib vs. placebo as an adjunct treatment to high-dose atorvastatin and standard of care on inflammatory biomarkers known to be predictive of secondary cardiovascular events in patients with a recent acute coronary syndrome (ACS). This new analysis examines the anti-inflammatory effects of varespladib, an inhibitor of secretory phospholipase A2 (sPLA2), in diabetic patients with a recent ACS... Anthera Pharmaceuticals' Press Release -
Tuesday, May 4, 2010
Anthera Pharmaceuticals : VARESPLADIB SHOWED EARLY BENEFIT IN DIABETIC PATIENT POPULATION
May 3, 2010 - ANTHERA PHARMACEUTICALS ANNOUNCES ADDITIONAL DATA FROM FRANCIS STUDY – Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced detailed results from a new biomarker analysis of the FRANCIS study. FRANCIS examined the effects of once-daily varespladib vs. placebo as an adjunct treatment to high-dose atorvastatin and standard of care on inflammatory biomarkers known to be predictive of secondary cardiovascular events in patients with a recent acute coronary syndrome (ACS). This new analysis examines the anti-inflammatory effects of varespladib, an inhibitor of secretory phospholipase A2 (sPLA2), in diabetic patients with a recent ACS... Anthera Pharmaceuticals' Press Release -
